| INTRODUCTION
A propofol intravenous infusion is a common means to provide sedation for children undergoing MRI. [1] [2] [3] [4] [5] Propofol enables both a smooth induction of sedation and a rapid recovery. Nevertheless, propofol is known to diminish systemic vascular resistance and decrease mean arterial pressure. 6 It may also cause decreased respiratory drive and upper airway obstruction. 6, 7 Propofol infusions may cause delayed emergence in higher doses over a prolonged time. 8 Occasionally,
deeper sedation is needed to avoid emergence during scans with higher Tesla MRI machines due to noise. 1 Larger doses of propofol in these settings may increase the side effects.
Dexmedetomidine is a selective alpha-2 adrenergic agonist that can be used as a primary anesthetic as well as an adjuvant to propofol or volatile anesthetics. As a single sedative agent for MRI, multiple reports have elucidated the superior features of dexmedetomidine over propofol with regard to hemodynamic stability and decreased risk of oxygen desaturation. However, when used as a sole sedative, large doses of dexmedetomidine are required and this may contribute to delayed recovery after sedation. [9] [10] [11] [12] [13] [14] Highdose dexmedetomidine may also cause hemodynamic instability including bradycardia and hypertension. 13, 15, 16 Dexmedetomidine has been reported to reduce propofol plasma concentrations and dose 17 required for sedation and suppression of motor response in healthy subjects. In a pediatric study, dexmedetomidine combined with propofol infusion reduced total propofol dose and decreased the incidence of airway complications. 18 We also wanted to explore the effect of low-dose dexmedetomidine on hemodynamic parameters from preinduction to up to 60 minutes after induction. In this study, we compared intravenous propofol infusion with or without a lowdose dexmedetomidine bolus prior to induction. We hypothesized that low-dose dexmedetomidine as an adjuvant would decrease the amount of propofol required for sedation, reduce the need for airway support, and improve hemodynamic stability.
| MATERIALS AND METHODS
After approval by the Institutional Review Board, we performed a retrospective chart review of all patients, age from 1 month old to absence of preinduction hemodynamic or respiratory vital signs, planned inhalational general anesthesia, or cases shorter than 30 minutes. We also excluded cases converted from use of intravenous infusion to inhalational general anesthesia. Children were divided into 2 groups; group P received propofol only; group D + P received intravenous bolus of dexmedetomidine followed by propofol bolus and infusion.
All the children were induced to a Ramsay Sedation Scale 19 status of at least 5 or 6 (sluggish or no response to light glabellar tap or loud auditory stimulus) suited for 1.5 Tesla (T) or 3T MRI. Then, sedation was maintained at a level in which noise and vibration in MRI does not cause movement of children. As the patient's were not stimulated during the procedure, it is possible that the level of sedation was deeper than 6 but with maintenance of appropriate vital signs. During the study period, our sedation using propofol without dexmedetomidine bolus (group P) consisted of an intravenous bolus of 2-3 mg/kg followed by a maintenance infusion started at 150-300 (median 250) lg/kg/min. For the sedation with dexmedetomidine (group D + P), a single intravenous bolus of dexmedetomidine (0.5 lg/kg) over 5 minutes was followed by the same intravenous bolus of propofol (2-3 mg/kg), then a maintenance infusion of propofol was started at 50-300 (median 150) lg/kg/min (Table 2 ). In cases exceeding 2 hours, some patients received an additional dexmedetomidine bolus (less than 0.5 lg/kg) at least 60 minutes after the initial bolus.
All anesthesiologists who provided sedation in MRI were pediatric anesthesiology fellowship trained with experience that ranged from 1 year to over 10 years (1-5 years, 10 anesthesiologists; 5-10 years, 3; longer than 10 years, 6). We surveyed these anesthesiologists to determine our routine care. Our overall response rate was 89.5% (17/19 All analyses were 2-sided with significance set at P < .05. Statistical computations were performed using Stat/IC 13.1(StataCorp, College Station, TX). The quality of MRI was blindly assessed by senior pediatric radiologist. Ten cases from each group were randomly selected.
| RESULTS
A total of 306 children were included in this study. One hundred and seventy-two children received propofol infusion only (group P). One hundred and twenty-nine children received propofol and intravenous bolus of dexmedetomidine (group D + P). Administered dexmedetomidine dose in group D + P was 0.50 (IQR: 0.45-0.62) lg/kg. There were 17 children whose MRI lasted longer than 2 hours received a second bolus of dexmedetomidine. The demographic data are shown in Table 1 . Details of preexisting conditions (19 in group P, 14 in D + P) that may affect respiration were obstructive sleep apnea (OSA) diagnosed by sleep study (5 in group P, 6 in D + P), obesity (BMI higher than 99 percentile by age prediction, 2 in group P), upper respiratory infection (URI) within 1 month (3 in P), chronic lung disease (2 in P, 1 in D + P), pulmonary edema (1 in P), airway compression by mass (4 in P, 1 in D + P), airway obstruction by craniofacial anomaly (1 in D + P),
hypotonia (2 in P, 2 in D + P), and Down syndrome (1 in D + P).
There were 2 cases with preexisting conditions (OSA, obesity) who were converted to laryngeal mask airway by provider's judgment.
The comparisons of administrated propofol were shown in Table 2 . There was no difference in bolus propofol dose (mg/kg) between groups P and D + P 
The difference in 2 groups was statistically significant (P < .0001, Chi-square test).
Line graphs (Figure 1 ) and linear regression of hemodynamic and respiratory parameters (HR, RR, MAP, SO 2 ) in relation to treatment group over time-based generalized estimating equation are demonstrated in Table 4 . There was a significant difference in HR between P and D + P group (coef = À7.68, 95%CI = À11.46, À3.91, P = .0001).
HR was consistently lower across time in D + P group compared to P group ( Figure 1A) . There was no significant interaction in HR between 2 groups over time (coef = À0.05, 95%CI = À0.11, 0.001, P = .06).
There was no difference in RR between P and D + P group (coef = 0.70, 95%CI = À0.47, 1.87, P = .24). There was no significant interaction in RR between 2 groups across time (coef = À0.02, 95% CI = À0.04, 0.007, P = .17). At the earlier time point (5 minutes after induction), RR was higher in D + P group compared to the P group but both groups started to be comparable at 30 minutes after induction ( Figure 1B ). There was a significant difference in MAP between P group and D + P group across time (coef = À0.06, 95% = À0.11, À0.02, P = .004). As shown in Figure 1C , the 2 groups were different at the earlier time point (5 minutes after induction) but they were comparable at time point 30 minutes after induction. There is no difference between P and D + P group in SO 2 across time points (coef = 0.001, 95%CI = À0.01, 0.01, P = .76). Both group showed the effects are similar ( Figure 1D ).
In MRI image quality evaluation, 9 out of 10 cases contained no motion artifact in either group. One case in each group contained minimal motion artifact that did not impede the ability of the radiologist to provide interpretation.
| DISCUSSION AND CONCLUSION
We found that a single low-dose dexmedetomidine bolus (0.5 lg/ kg with a second bolus for prolonged scans) as an adjuvant to propofol infusion decreased the propofol requirement for children undergoing MRI. There was also a significant reduction in the number of children who required airway support and they remained hemodynamically stable. The ideal medications for sedation for children undergoing MRI should maintain spontaneous ventilation, provide hemodynamic stability, ensure patient immobility, allow easy drug titration, and no prolong recovery time. As a single agent for sedation, propofol has been popular as it provides rapid and smooth induction to deep sedations levels and ensures patient immobility for nonpainful procedures. 2, 3 However, propofol may cause hemostatic instability due to diminished systemic vascular resistance, hypoventilation due to decreased respiratory drive, and upper airway obstruction due to decreased tone of pharyngeal muscles in dose-dependent fashion. 6, 7 Decreasing the propofol infusion rate may reduce these side effects, but the risk of emergence during the procedure may increase. On the contrary, high-T A B L E 1 Demographic and baseline data between P and D + P groups Other authors have shown that dexmedetomidine can be added to propofol sedation and will decrease the propofol requirement to achieve optimal sedation or total intravenous anesthesia for surgical procedures. In these reports, the recommended loading dose
(1 lg/kg infusion over 10 minutes) with or without maintenance (0.4-1.0 lg/kg/h) was combined with a propofol infusion. 17, [22] [23] [24] Le
Guen reported that dexmedetomidine decreased the propofol requirement by 30%. 22 A common practice in our institution is to administer a half of the recommended loading dose of dexmedetomidine. Our rational for the lower dose of dexmedetomidine was to reduce the risk of bradycardia that can occur when it is administered as bolus. In our study, there was still a propofol-sparing effect with low-dose dexmedetomidine (initial 0.5 lg/kg bolus with or without second bolus 0.5 lg/kg for scans >2 hours). The incidence of deepening sedation was similar in both groups (Table 3) .
Deepening of sedation occurred more frequently in the propofol only group than the low-dose dexmedetomidine group within 60 minutes after start of MRI (difference was not significant). The propofol-sparing effect could be expected given the lower starting dose of the propofol infusion. However, the clinicians adjusted the propofol infusion during the case based upon clinical findings and could have increased it if needed. In our study, the decrease in
propofol was approximately 31% total dose and 35% in the infusion rate (Table 2 ). This result is comparable to other studies using dexmedetomidine (1 lg/kg) bolus. 18, 22 In a recent study reported by Borosi, the addition of dexmedetomidine (1 lg/kg) significantly prolonged discharge time. In our study, the low-dose dexmedetomidine bolus did not affect recovery time, even with second bolus (Table 2) .
One of the greatest clinical differences between our groups was the reduced need for airway support in the D + P group compared to propofol alone. Although the incidence of airway support was low in both groups, it was significantly lower in dexmedetomidine bolus group. Due to a decreased propofol requirement, a low-dose dexmedetomidine bolus seemed associated with improved airway patency and maintenance of ventilation (Table 3 ). It is notable that incidence of O 2 flow increase happened more often in propofol only group (difference was not significant) ( Table 3 ).
There was a decrease in heart rate after induction throughout the duration of the measurements in both groups ( Figure 1A ).
Heart rate in the propofol was significantly higher than in the dexmedetomidine bolus group through 60 minutes. However, there was no significant difference between 2 groups over time-based generalized estimating equation. The maximal decrease in heart rate from baseline with the addition of low-dose dexmedetomidine (0.5 lg/kg) was only 10%-12% which compares favorably to the heart rate decrease of 15%-25% reported in high-dose dexmedetomidine studies. 9, 12, 13, 25 The influence of low-dose dexmedetomidine on mean arterial pressure (MAP) was seen over time in 60 minutes. In fact, the decrease in MAP from preinduction values was larger in the propofol only group at 5 minutes after induction as compared to the low-dose dexmedetomidine adjuvant group (25% vs 8% decrease). We did find a decrease in MAP for the propofol only group that is comparable to the 15%-31% occurrence seen in other studies. 2, 9 As for clinically significant hypotension defined as more than 20% drop from baseline (preanesthesia) MAP, the number of episodes is significantly higher in the propofol only group compared to low-dose dexmedetomidine group (Table 3) . Based on our survey among our department anesthesiologists, we anticipated far more cases in both groups (1.2% and 1.6% in each group) to be given fluid therapy for hypotension. This may be a dissociation of actual practice from our principle.
The results of our study need to be considered in light of its limitations. As a retrospective study, the use of dexmedetomidine was not randomized but at the discretion of the anesthesiologist. Upon review we do believe that the 2 groups were similar (Table 1) . We have a common management of this patient population in our institution as shown in the summary of our survey in materials and methods. However, there could be alterations that we could not elicit from reviewing the medical records. The propofol infusion used for maintenance of sedation is higher than some groups may be comfortable with, but these doses have certainly been reported in the literature. The airway interventions reported do not include brief episodes of obstruction that required repositioning. Those reported are more significant interventions of placing an airway device. Furthermore, events in both groups were identified and recorded in a similar fashion. Although statistically significant difference was identified, the incidence of airway interventions was quite low in both groups.
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F I G U R E 1 Hemodynamic and respiratory parameters during the sedation. A, heart rate (HR, /min); B, respiratory rate (RR, /min); C, mean arterial pressure (MAP, mm Hg); D, oxygen saturation (SO 2, %). Time starts at the time of induction (0). Group P (propofol only); Group D + P (propofol with dexmedetomidine bolus). Error bars represent SD. A, There was a significant difference in 2 groups across time points (P < .0001). B, There was no difference between 2 groups (P = .17). C, There was a significant difference in MAP across the time (P = .004). Two groups were different at 5 min after induction. D, There was no difference between 2 groups in SO 2 (P = .76)
There may be 1 additional theoretical benefit of using the combination of dexmedetomidine and propofol given the recent Food and Drug Administration (FDA) warning regarding general anesthetics and sedation drugs for young children and pregnant women due to the potential for neurotoxicity. Although supporting clinical data were limited for the warning, the FDA stressed the importance of avoiding prolonged use (longer than 3 hours) and repeated use of these drugs in younger age (less than 3 years old). Propofol is listed in the warning, whereas dexmedetomidine is not. In theory, neurotoxicity is dependent on the amount of anesthetics/sedatives given through the course of a procedure. It is reasonable to limit the amount of propofol given to younger children, especially those who may undergo sedation repeatedly.
We concluded that low-dose dexmedetomidine single bolus Group P, propofol only; group D + P, propofol infusion with dexmedetomidine bolus.
